Executive Management Team
Mr. Darling joined Anika as President in July 2017, bringing more than 20 years of extensive experience in executive management and leadership from publicly-traded, commercial-stage companies, including Abbott Laboratories, Baxter Healthcare, Smith & Nephew, CONMED, and Wyeth-Ayerst. Most recently, Mr. Darling held executive leadership positions with two small privately held orthopedic companies. Prior to these roles, Mr. Darling held senior level executive positions at CONMED Corporation, a global, publicly-held, diversified medical device company, as Global President of its wholly-owned subsidiary, Linvatec Corporation, and as Executive Vice President of Global Corporate Commercial Operations. At CONMED, Mr. Darling led five global business units with approximately $760 million in annual revenues and re-energized the organizational efforts in sales, marketing, R&D, and business development activities that allowed the company to expand its portfolio of product offerings to its customers. Mr. Darling oversaw the launch and commercialization of many key new products while at Linvatec including several new sports medicine technologies in the shoulder (Shoulder Restoration System, Y-Knot Shoulder Anchor line), along with new products in the knee and hip joints. Before joining CONMED, Mr. Darling was Senior Vice President and General Manager for the sports medicine and biologics business at Smith & Nephew, where he played an important role in defining a global strategy that propelled the company to a leadership position in the sports medicine field. While at Smith & Nephew, Mr. Darling and his team were pioneers in developing the Hip Arthroscopy space from a commercial perspective. Mr. Darling launched his career at Abbott Laboratories where he was involved in the commercialization efforts of many pharmaceutical products in the neuroscience, antimicrobial, cardiovascular, and HIV treatment space. While at Abbott Laboratories, he held management positions in sales and marketing before joining Wyeth-Ayerst Pharmaceuticals in roles of marketing for the pain and inflammation and women's healthcare franchises. He later joined Baxter Healthcare as a Vice President of marketing and health systems. Mr. Darling holds a Bachelor of Arts in Political Science from Syracuse University.
On April 1, 2013 Sylvia Cheung was appointed as Chief Financial Officer. Ms. Cheung brings to Anika a substantial number of years of financial and general management experience. Prior to her current position, Sylvia was the Vice President of Strategic Processes; and previously, she served as the General Manager for the company's Italian-based subsidiary, Anika S.r.l. She joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Sylvia led the company's integration of Anika S.r.l. subsequent to its acquisition in 2009.
Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Sylvia worked for PricewaterhouseCoopers, LLP as an Audit Senior Associate.
Sylvia holds a bachelor of business administration degree in accounting from the University of Massachusetts in Amherst, a master's degree in business administration from Boston University, and is a Certified Public Accountant (inactive).
Richard Hague joined Anika Therapeutics, Inc. as Chief Commercial Officer on October 26, 2015. Most recently, Richard served as Vice President, Sales and Marketing, for TEI Medical, where he was responsible for driving revenue growth, building the sales and marketing teams, and implementing strategies to drive national account and federal and private payer acceptance of the company’s technology platform. He previously was Vice President, Sales, Marketing and Commercial Operations at Sanofi Biosurgery, where he led the build out of the global sales and marketing team and oversaw all commercial activities in the U.S. for the company’s Cell Therapy and Regenerative Medicine business. Richard’s prior experience also includes leadership positions at Genzyme Biosurgery as Senior Director and Head of U.S. Sales, and Northeast Regional Sales Director.
Richard holds a B.S. in Marketing from the University of Connecticut.
Edward Ahn, Ph.D., joined Anika Therapeutics, Inc. as Chief Technology and Strategy Officer on October 30, 2014. Most recently, Dr. Ahn was Managing Director and Chief Science Officer at MedCap Advisors where he built merger strategies, strategic partnerships and licensing agreements for emerging medical device, biotechnology and biological organizations with a focus on regenerative medicine. Prior to his work at MedCap, Dr. Ahn was Vice President of Product Development for Pioneer Surgical Biologics. In this role Dr. Ahn directed Pioneer Surgical Biologic's product development policies, objectives and initiatives. He has also served as Chief Executive Officer, Chief Technology Officer and Founder of Angstrom Medica, Inc., a company based upon his doctoral thesis work and focused on commercializing nanotechnology in the area of Orthopedics.
Dr. Ahn holds a B.S. in Chemical Engineering from Stanford University and M.S. (Chemical Engineering Practice) and Ph.D. in Chemical Engineering from Massachusetts Institute of Technology.
Tom Finnerty joined Anika Therapeutics, Inc. as the Company’s Chief Human Resources Officer on October 30, 2017. Most recently, Tom was a strategic human capital consultant with Anika Therapeutics. Prior to his work at Anika, Tom was the Senior Vice President of Human Resources at Smith & Nephew where he was responsible for delivering value added programs, processes, and leadership in all areas of global human capital management to over 10,000 employees. Prior to his time at Smith & Nephew, Mr. Finnerty served as Executive Director of Human Resources at Novartis/Chiron Diagnostics. Tom launched his career in human resources at The Foxboro Company, a global enterprise focused on designing and manufacturing innovative process control products and systems.
Tom holds a Masters in Business Administration from Babson College, and a Bachelor of Science in Business from the University of Massachusetts.
Steven Chartier joined Anika Therapeutics, Inc. as the Company’s Vice President of Regulatory and Clinical Affairs on August 28, 2017. Most recently, Steven was Vice President of Regulatory Affairs and Quality Assurance at Augmenix Inc. where he was responsible for all Regulatory and Quality functions and activities within the organization. Prior to his work at Augmenix, Steven was the Chief Operations Officer and a member of the executive management team at Pixarbio Corporation where he oversaw the development of and led all Regulatory, Quality, and Clinical programs for the organization. Steven has also held senior leadership roles at a number of other Medical Device, Life Sciences, and Pharmaceutical organizations including Infraredx, Inc., Nucryst Pharmaceuticals, Inc., and Biogen, Inc. Steven launched his career in clinical research at the Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center.
Steven holds a B.A. in Psychology from Saint Anselm College and has maintained a Regulatory Affairs Certification (RAC) since 2003.
On March 24, 2014, Steven Cyr joined Anika Therapeutics Inc. as the Vice President of Human Resources. He is responsible for all of the global human capital activities and programs of the company. Steve comes to Anika from DENTSPLY International, formerly Astra Tech Inc.(Astra Zeneca) in Waltham, MA where he worked from 2006 to 2014. Steve served as Vice President, Human Resources DENTSPLY Implants Division (North America). He was responsible for leading and managing all aspects of HR for the Dental Implant and Urology divisions. The employee population included sales, marketing, operations, R&D, manufacturing, and G&A. Previously, Steve was employed by Sepracor Pharmaceuticals in Marlborough, MA as the Associate Director Human Resources, Client Services. In addition, he has worked as a consultant supporting HR initiatives at Monster Worldwide in Maynard and DePuy AcroMed Medical Devices in Raynham. Furthermore, he has held positions with StorageNetworks, Inc., The Avicon Group, Inc., i2 Technologies, Cambridge Technology Partners, TASC, and Wang Information Services Corp.
Steve has a B.S. from the University of Maine in Liberal Arts Psychology (Honors), and an M.A. in Industrial /Organizational Psychology (Honors) from the University of New Haven.
Alexei Goraltchouk joined Anika Therapeutics, Inc. as Vice President of Operations on June 11, 2018. Most recently, Mr. Goraltchouk served as Vice President of Operations at Avedro, Inc. where he was responsible for managing all aspects of Clinical and Commercial Production, Technical Operations, Procurement, and Supply Chain Management for the organization. Prior to his work at Avedro, Alex held senior leadership roles in Operations, Supply Chain Management, and R&D for several firms including Allergan, Inc., Regeneron, Inc., and Biogen, Inc.
Mr. Goraltchouk holds a B.S. in Materials Engineering and an M.S. in Chemical Engineering from the University of Toronto, as well as an M.B.A. and M.S. in Finance from Indiana University. He is a Cornell Certified Six Sigma Black Belt and holds professional certifications from Stanford University (Genetics and Genomics), Massachusetts Institute of Technology (Supply Chain Management), and the Project Management Institute (Project Management Professional).
On January 1, 2018, Charles Sherwood III was appointed to the position of Vice President Corporate Legal Counsel. Charles provides leadership to Anika’s internal legal function and has wide-ranging responsibilities associated with guiding the company through the current legal and regulatory environment worldwide. Prior to his current position, Charles held progressively senior roles within Anika’s legal department, and he has been responsible for a number of corporate projects.
Charles holds a B.A. in Economics from Middlebury College and a J.D. from Vanderbilt University, and he is admitted to the Massachusetts Bar.
Ellen Snow joined Anika Therapeutics, Inc. as Vice President of Finance and Corporate Controller on September 26, 2016. Most recently, Ms. Snow worked as a consultant for CFGI, a specialized financial consulting firm where she provided financial leadership to companies experiencing a range of routine and complex business scenarios. Prior to her work at CFGI, Ms. Snow was the Senior Director and Controller for Benchmark Senior Living where she streamlined their financial reporting processes and restructured, developed, and managed a large team of accountants performing with a broad range of responsibilities including acquisition and strategic initiatives. Before that she held CFO and Corporate Controller positions at organizations including Catalyst Health Ventures and Bain Willard Companies, LP. Ms. Snow began her career in public accounting with Price Waterhouse and Ernst & Young, LLP.
Ellen holds a B.S. in Accounting from Merrimack College, where she graduated Summa Cum Laude, and she is a Certified Public Account (inactive).